Validation of a Remediation Method for Memory Disorders Using Motor and Emotional Encoding in Patients With Alzheimer's Disease (ADAE)

Validation of a Remediation Method for Memory Disorders Using Motor and Emotional Encoding in Patients With Alzheimer's Disease (AD)

Memories are more robust when they are multitraced. This means that the more a piece of information is mediated by different sensory inputs, the more resistant it is to being forgotten. Many works in the field of embodied cognition show that new learnings are better recalled over the long term when they are learned during body mobilization. Other works show that musical stimulation could be a good way of eliciting physiological and emotional states more favorable to the memorization of new contents. However, to date, no studies have examined the positive effects of these two tools combined in Alzheimer's disease. The investigators suggest that it is possible to optimize memory in Alzheimer's disease by referring to their motor and emotional resources. The hypothesis is that information will be better recalled with multimodal enriched learning.

Study Overview

• Status: Recruiting
• Conditions: Alzheimer Disease
• Intervention / Treatment: Behavioral: Cognitive tests

Detailed Description

In a within subjects design, all patients take part in four conditions. In each condition, sentences describing actions will be displayed. In a control condition, they will be asked to read the sentence aloud; in a motor-only condition, they will also be asked to mime the sentence; in an emotional-only condition, they will be asked to read the sentence while listening to music; and in a dual condition, they will be asked to both mime and listen to music. Immediately after each condition, they will realize a recognition task. The main criterion used in our statistical analyses will be the discrimination threshold.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Céline BORG, MD; Phone Number: +33 (0)477127805; Email: celine.borg@univ-st-etienne.fr

Study Locations

• France
  • Grenoble, France
    • Recruiting
    • CHU Grenoble
    • Contact: Mathilde SAUVEE, Md
    • Principal Investigator: Mathilde SAUVEE, Md
    • Sub-Investigator: Olivier MOREAUD, Md
  • Saint-Étienne, France, 42055
    • Recruiting
    • CHU DE SAINT-ETIENNE
    • Principal Investigator: Céline BORG, MD
  • Villeurbanne, France
    • Recruiting
    • HCL
    • Contact: Isabelle ROUCH, Md
    • Principal Investigator: Isabelle ROUCH, MD
    • Sub-Investigator: Céline BORG

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of Alzheimer's disease by one of the consulting physicians, neurologist and/or geriatrician of whom the patient has been informed.
• Early stage (MMSE ≥ 22)
• Neuropsychological assessment within 6 months of inclusion.
• Affiliation with a social security scheme
• Age equal to or greater than 60
• French mother tongue
• Agreement to participate / signature of consent form

Exclusion Criteria:

• Uncorrected perceptual disorders
• Other neurological or psychiatric history
• Inability to communicate
• Delusional or psychotic state
• Person unable to give informed consent
• Refusal to participate
• Participation in a study on a drug/medical device/care technique likely to affect cognitive functions

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Patients with Alzheimer disease; Patients will perform experimental task in four conditions : control, mime, emotion, dual

Behavioral: Cognitive tests; . Patients will perform experimental task in four conditions : control, mime, emotion, dual In a control condition : they will be asked to read the sentence aloud; in a motor-only condition, they will also be asked to mime the sentence; in an emotional-only condition, they will be asked to read the sentence while listening to music; in a dual condition, they will be asked to both mime and listen to music. Immediately after each condition, they will realize a recognition task; quiz : Geneva Music Induced Checklist, GMIAC, Coutinho & Scherer, 2017

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
"Discrimination score"	Comparison of the recognition score obtained in each of the experimental conditions to the recognition score obtained in the control condition The score = the Number of correct answer (0 to 15, the higher score means better outcome)	Weeks: 2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
"Geneva Music-Induced Affect Checklist" scale	Analysis Geneva Music-Induced Affect Checklist scale results. It is composed of 4 sub-score dimensions such as valence, activation, tension (stress level) and pleasure (14 items scale 1: "not at all" to 5 "hugely, it's a qualitative scale)	Weeks: 2

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Saint Etienne
• Investigators: Principal Investigator: Céline BORG, MD, CHU Saint-Etienne

Study record dates

Study Major Dates

• Study Start (Actual): January 22, 2024
• Primary Completion (Estimated): April 1, 2025
• Study Completion (Estimated): May 1, 2025

Study Registration Dates

• First Submitted: October 23, 2023
• First Submitted That Met QC Criteria: October 23, 2023
• First Posted (Actual): October 27, 2023

Study Record Updates

• Last Update Posted (Actual): February 12, 2024
• Last Update Submitted That Met QC Criteria: February 9, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Alzheimer; Action memory; Musical memory
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease; Memory Disorders
• Other Study ID Numbers: 23CH154; ANSM (Other Identifier: 2024-A00286-41)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No